Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $78.86 Consensus PT from Analysts

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $78.8571.

A number of research firms have recently issued reports on ESTA. Mizuho raised their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Canaccord Genuity Group lifted their price objective on shares of Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. JPMorgan Chase & Co. upped their price objective on shares of Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Finally, Citigroup increased their price objective on shares of Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th.

Institutional Investors Weigh In On Establishment Labs

Several hedge funds have recently bought and sold shares of ESTA. Quarry LP acquired a new position in shares of Establishment Labs in the third quarter valued at approximately $34,000. State of Wyoming acquired a new stake in Establishment Labs during the 3rd quarter worth approximately $71,000. Osaic Holdings Inc. boosted its stake in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares during the period. CWM LLC grew its holdings in Establishment Labs by 45.9% in the 2nd quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after buying an additional 686 shares in the last quarter. Finally, PharVision Advisers LLC acquired a new position in Establishment Labs in the 3rd quarter valued at $203,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Stock Performance

Shares of ESTA opened at $67.51 on Wednesday. The company has a market cap of $1.96 billion, a PE ratio of -23.77 and a beta of 0.92. The firm has a 50-day moving average of $69.83 and a 200-day moving average of $52.28. Establishment Labs has a one year low of $26.56 and a one year high of $78.24. The company has a debt-to-equity ratio of 15.06, a current ratio of 3.33 and a quick ratio of 2.10.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.16. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. The business had revenue of $53.78 million during the quarter, compared to the consensus estimate of $52.28 million. During the same period last year, the business posted ($0.59) EPS. Establishment Labs’s revenue was up 33.8% on a year-over-year basis. As a group, equities analysts forecast that Establishment Labs will post -2.41 earnings per share for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.